Key facts
- This page summarizes Peter A. Thompson's Form 4 filing for Corvus Pharmaceuticals, Inc. (CRVS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 15 Aug 2022, 18:47.
Peter A. Thompson - 11 Aug 2022 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- CRVS
- Reported as of
- 11 Aug 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Aug 2022, 18:47:25 UTC
- Prior SEC filing
- 28 Jun 2022
- Next SEC filing
- 16 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Leiv Lea, as Attorney-in-Fact for Peter A. Thompson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Peter A. Thompson filed Form 4 for Corvus Pharmaceuticals, Inc. (CRVS) on 15 Aug 2022.
Change
- Previous filing in this sequence was filed on 28 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRVS
holding
Common Stock, $0.0001 par value
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,943,654
- Date
- 11 Aug 2022
- Ownership
- See Footnotes
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRVS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- Price
- $0.000000
- Shares after
- 15,000
- Date
- 11 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $0.9650
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is a member of Advisors.
Footnote F2
Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purpose.
Footnote F3
The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Footnote F4
The Reporting Person is obligated to transfer any shares issued pursuant to any equity grants made to him by the Issuer, or the economic benefits thereof, to Advisors and certain of its related entities. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.